International Journal of Molecular Sciences · 2014 · 51 citations · 46 references
MedicineNephrologyPharmacologyApoptosisCell SignalingRenal PathophysiologyChronic Kidney DiseaseEndoplasmic Reticulum Stress-induced ApoptosisEndothelial DysfunctionRenal DiseaseRenal FibrosisRenal PharmacologyC-jun N-terminal Kinase SignalingEndoplasmic Reticulum StressEr Stress SensorsJnk Pathway ActivationJnk Signaling PathwayJnk-mediated ApoptosisRenal ApoptosisRenal Fibrosis Mechanisms
Asymmetric dimethylarginine (ADMA) is considered an independent mortality and cardiovascular risk factor in chronic kidney disease (CKD) patients, and contributes to the development of renal fibrosis. Quercetin (QC), a natural component of foods, protects against renal injury. Here, we explored the possible mechanisms that are responsible for ADMA-induced renal fibrosis and the protective effect of QC. We found that ADMA treatment activated the endoplasmic reticulum (ER) stress sensor proteins phosphorylated protein kinase RNA-activated-like ER kinase (PERK) and inositol requiring-1α (IRE1), which correspondingly induced C/EBP homologous protein (CHOP) expression and phosphorylated c-Jun N-terminal kinase (JNK) phosphorylation in glomerular endothelial cells (GEnCs). Following this, ADMA promoted ER stress-induced apoptosis and resulted in transforming growth factor β (TGF-β) expression in GEnCs. SP600125, an inhibitor of JNK, and CHOP siRNA protected against ADMA-induced cell apoptosis and TGF-β expression. QC prevented ADMA-induced PERK and IRE1 apoptotic ER stress pathway activation. Also, ADMA-induced GEnCs apoptosis and TGF-β expression was reduced by QC. Overexpression of CHOP blocked QC-mediated protection from apoptosis in ER stressed cells. Overall, these observations indicate that ADMA may induce GEnCs apoptosis and TGF-β expression by targeting the PERK-CHOP and IRE1-JNK pathway. In addition, drugs such as QC targeting ER stress may hold great promise for the development of novel therapies against ADMA-induced renal fibrosis.
46
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
A. Leone, S. Moncada, Patrick Vallance et al. · The Lancet · 1992 · 2.1K citations
Medicine, Nephrology, Pharmacology +11